NCT00224471View on ClinicalTrials.gov

Study to Compare Safety and Immunogenicity of Commercial Scale Consistency Lots of Herpes Simplex Vaccine

PHASE3CompletedINTERVENTIONAL
Enrollment

671

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

September 30, 2005

Study Completion Date

January 31, 2006

Conditions
Herpes Simplex
Interventions
BIOLOGICAL

GSK208141 vaccine

3 IM doses

Trial Locations (13)

9000

GSK Investigational Site, Ghent

29403

GSK Investigational Site, Charleston

45229

GSK Investigational Site, Cincinnati

80401

GSK Investigational Site, Golden

84109

GSK Investigational Site, Salt Lake City

84121

GSK Investigational Site, Salt Lake City

85201

GSK Investigational Site, Mesa

92708

GSK Investigational Site, Fountain Valley

98105

GSK Investigational Site, Seattle

77555-0188

GSK Investigational Site, Galveston

T6G 2C8

GSK Investigational Site, Edmonton

V6H 3N1

GSK Investigational Site, Vancouver

G1E 7G9

GSK Investigational Site, Beauport

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY